242 related articles for article (PubMed ID: 37852906)
1. Development of bispecific T cell engagers: harnessing quantitative systems pharmacology.
Qi T; Liao X; Cao Y
Trends Pharmacol Sci; 2023 Dec; 44(12):880-890. PubMed ID: 37852906
[TBL] [Abstract][Full Text] [Related]
2. Optimizing Clinical Translation of Bispecific T-cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model.
Liao X; Qi T; Zhou J; Liu C; Cao Y
Clin Pharmacol Ther; 2024 May; ():. PubMed ID: 38751031
[TBL] [Abstract][Full Text] [Related]
3. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
Tian Z; Liu M; Zhang Y; Wang X
J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
[TBL] [Abstract][Full Text] [Related]
4. Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment.
Yuraszeck T; Kasichayanula S; Benjamin JE
Clin Pharmacol Ther; 2017 May; 101(5):634-645. PubMed ID: 28182247
[TBL] [Abstract][Full Text] [Related]
5. A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell-Mediated Immune Response against EGFR-Expressing Tumors.
King LA; Toffoli EC; Veth M; Iglesias-Guimarais V; Slot MC; Amsen D; van de Ven R; Derks S; Fransen MF; Tuynman JB; Riedl T; Roovers RC; Adang AEP; Ruben JM; Parren PWHI; de Gruijl TD; van der Vliet HJ
Cancer Immunol Res; 2023 Sep; 11(9):1237-1252. PubMed ID: 37368791
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model.
Ma H; Wang H; Sové RJ; Wang J; Giragossian C; Popel AS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32859743
[TBL] [Abstract][Full Text] [Related]
7. A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid Tumor.
Ma H; Wang H; Sove RJ; Jafarnejad M; Tsai CH; Wang J; Giragossian C; Popel AS
AAPS J; 2020 Jun; 22(4):85. PubMed ID: 32533270
[TBL] [Abstract][Full Text] [Related]
8. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
[TBL] [Abstract][Full Text] [Related]
9. Strategies for clinical dose optimization of T cell-engaging therapies in oncology.
Ball K; Dovedi SJ; Vajjah P; Phipps A
MAbs; 2023; 15(1):2181016. PubMed ID: 36823042
[TBL] [Abstract][Full Text] [Related]
10. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
11. Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma.
Abrams RE; Pierre K; El-Murr N; Seung E; Wu L; Luna E; Mehta R; Li J; Larabi K; Ahmed M; Pelekanou V; Yang ZY; van de Velde H; Stamatelos SK
Sci Rep; 2022 Jun; 12(1):10976. PubMed ID: 35768621
[TBL] [Abstract][Full Text] [Related]
12. Bispecific antibodies for immune cell retargeting against cancer.
Chen RP; Shinoda K; Rampuria P; Jin F; Bartholomew T; Zhao C; Yang F; Chaparro-Riggers J
Expert Opin Biol Ther; 2022 Aug; 22(8):965-982. PubMed ID: 35485219
[TBL] [Abstract][Full Text] [Related]
13. Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.
Xiao X; Cheng Y; Zheng X; Fang Y; Zhang Y; Sun R; Tian Z; Sun H
Front Immunol; 2023; 14():1113303. PubMed ID: 37114050
[TBL] [Abstract][Full Text] [Related]
14. A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART
Betts A; Haddish-Berhane N; Shah DK; van der Graaf PH; Barletta F; King L; Clark T; Kamperschroer C; Root A; Hooper A; Chen X
AAPS J; 2019 May; 21(4):66. PubMed ID: 31119428
[TBL] [Abstract][Full Text] [Related]
15. Conditionally active T cell engagers for the treatment of solid tumors: rationale and clinical development.
Chen TT
Expert Opin Biol Ther; 2022 Aug; 22(8):955-963. PubMed ID: 35857922
[TBL] [Abstract][Full Text] [Related]
16. Using quantitative systems pharmacology modeling to optimize combination therapy of anti-PD-L1 checkpoint inhibitor and T cell engager.
Anbari S; Wang H; Zhang Y; Wang J; Pilvankar M; Nickaeen M; Hansel S; Popel AS
Front Pharmacol; 2023; 14():1163432. PubMed ID: 37408756
[TBL] [Abstract][Full Text] [Related]
17. Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety.
Ellerman D
Methods; 2019 Feb; 154():102-117. PubMed ID: 30395966
[TBL] [Abstract][Full Text] [Related]
18. A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies.
Lameris R; Ruben JM; Iglesias-Guimarais V; de Jong M; Veth M; van de Bovenkamp FS; de Weerdt I; Kater AP; Zweegman S; Horbach S; Riedl T; Winograd B; Roovers RC; Adang AEP; de Gruijl TD; Parren PWHI; van der Vliet HJ
Cell Rep Med; 2023 Mar; 4(3):100961. PubMed ID: 36868236
[TBL] [Abstract][Full Text] [Related]
19. From Cold to Hot: Changing Perceptions and Future Opportunities for Quantitative Systems Pharmacology Modeling in Cancer Immunotherapy.
Lemaire V; Bassen D; Reed M; Song R; Khalili S; Lien YTK; Huang L; Singh AP; Stamatelos S; Bottino D; Hua F
Clin Pharmacol Ther; 2023 May; 113(5):963-972. PubMed ID: 36282521
[TBL] [Abstract][Full Text] [Related]
20. Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia.
Algeri M; Del Bufalo F; Galaverna F; Locatelli F
Expert Rev Hematol; 2018 Dec; 11(12):945-956. PubMed ID: 30358451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
